Afatinib. Afatinib+Trametinib. Afatinib Log [µM]. %. A. TP. (n or m aliz ed to. D. M. S. O). -4. -3. -2. -1. 0. 50. 100. Trametinib. Trametinib Log [µM]. -2. -1. 0. 1.
Figure 4-Source data 1
Combination therapy: EGFRi & MEKi P18T
P18T KRASG12D 100
50
-1
0
Drug Log [µM]
-1
0
Drug Log [µM]
% ATP (normalized to DMSO)
-2
-1
0
Drug Log [µM]
1
(n = 4/ 6/ 2)
% ATP (normalized to DMSO)
Lapatinib Selumetinib Lapatinib + Selumetinib
50
0 -2
-1
0
Drug Log [µM]
Trametinib Log [µM] -3
1
-2
-4
-1 Trametinib Afatinib Afatinib+Trametinib
50
-4
-1
Afatinib Log [µM]
Trametinib Log [µM] -3
0
-2
-4
-1
0
Lapatinib Log [µM]
Trametinib Log [µM] -3
-2
-1
Dacomitinib Log [µM]
0
1
(n = 4/ 7/ 2)
-1
-1
0
Afatinib Log [µM]
Trametinib Log [µM] -3
1
(n = 3/ 4/ 2)
-2
-1 Trametinib Dacomitinib Dacomitinib+Trametinib
-2
-4
-1
50
-2
50
1
Trametinib Dacomitinib Dacomitinib+Trametinib
-3
100
(n = 4/ 4/ 2)
100
-2
-2
-4
-1
0
-2
Trametinib Log [µM]
1
(n = 2/ 6/ 2)
Trametinib Afatinib Afatinib+Trametinib
(n = 4/ 5/ 2)
50
0
Drug Log [µM]
50
1
Trametinib Lapatinib Lapatinib+Trametinib
100
-1
100
0
-2
-2
(n = 4/ 8/ 2)
% ATP (normalized to DMSO)
% ATP (normalized to DMSO) % ATP (normalized to DMSO)
